Skip to main content
Journal cover image

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry.

Publication ,  Journal Article
Khariton, Y; Fonarow, GC; Hellkamp, A; Thomas, L; Nassif, ME; Butler, J; Duffy, CI; Albert, NM; Spertus, JA
Published in: ESC Heart Fail
February 2021

AIMS: The aim of our study was to investigate heterogeneity of health status treatment response of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS: We leveraged data from CHAMP-HF, an observational registry of 140 US clinics and 5026 outpatients with chronic HFrEF, where health status was serially assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 Overall Summary Scale (range from 0 to 100; ≥20-point improvement is a very large improvement). In 334 patients newly initiated on sacubitril/valsartan, we used hierarchical multivariable logistic regression (13 patient-level characteristics as well as baseline KCCQ-12 score) to calculate the odds ratio (OR) of any characteristic being associated with a very large health status improvement. A total of 104/334 (31.1%) of patients achieved the primary endpoint, where only worse baseline health status [KCCQ-12 score of 0-60 points had an OR = 0.86/5-point higher score (CI 0.79, 0.93)], and those with a KCCQ-12 score of 60-80 points had an OR = 0.61/5-point higher score (0.45-0.82), which was associated with a very large benefit. No other patient characteristic was associated with a very large health status improvement (P > 0.05). CONCLUSIONS: We found that, after initiation of sacubitril/valsartan, only worse baseline health status was associated with very large health status improvement. Accordingly, a trial of therapy-particularly in those with worse symptoms, function, and quality of life-and assessing treatment response are likely to be the best prospective strategy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

ESC Heart Fail

DOI

EISSN

2055-5822

Publication Date

February 2021

Volume

8

Issue

1

Start / End Page

710 / 713

Location

England

Related Subject Headings

  • Valsartan
  • Stroke Volume
  • Registries
  • Quality of Life
  • Prospective Studies
  • Humans
  • Heart Failure
  • Health Status
  • Drug Combinations
  • Biphenyl Compounds
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khariton, Y., Fonarow, G. C., Hellkamp, A., Thomas, L., Nassif, M. E., Butler, J., … Spertus, J. A. (2021). Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. ESC Heart Fail, 8(1), 710–713. https://doi.org/10.1002/ehf2.12981
Khariton, Yevgeniy, Gregg C. Fonarow, Ann Hellkamp, Laine Thomas, Michael E. Nassif, Javed Butler, Carol I. Duffy, Nancy M. Albert, and John A. Spertus. “Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry.ESC Heart Fail 8, no. 1 (February 2021): 710–13. https://doi.org/10.1002/ehf2.12981.
Khariton Y, Fonarow GC, Hellkamp A, Thomas L, Nassif ME, Butler J, et al. Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. ESC Heart Fail. 2021 Feb;8(1):710–3.
Khariton, Yevgeniy, et al. “Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry.ESC Heart Fail, vol. 8, no. 1, Feb. 2021, pp. 710–13. Pubmed, doi:10.1002/ehf2.12981.
Khariton Y, Fonarow GC, Hellkamp A, Thomas L, Nassif ME, Butler J, Duffy CI, Albert NM, Spertus JA. Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. ESC Heart Fail. 2021 Feb;8(1):710–713.
Journal cover image

Published In

ESC Heart Fail

DOI

EISSN

2055-5822

Publication Date

February 2021

Volume

8

Issue

1

Start / End Page

710 / 713

Location

England

Related Subject Headings

  • Valsartan
  • Stroke Volume
  • Registries
  • Quality of Life
  • Prospective Studies
  • Humans
  • Heart Failure
  • Health Status
  • Drug Combinations
  • Biphenyl Compounds